ZBZineb Benbrahim

Zineb Benbrahim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zineb Benbrahim has a total of 201 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effective and ineffective psychological adjustment in breast cancer patients before receiving neoadjuvant chemotherapy: insights from a cohort study

    by Majid Omari, Salima Kriya, Sara Nadi, Ghita Zerhouni, Chaymae El Abbas, Achraf El Asri, Zineb Benbrahim, Nawfel Mellas, Karima El Rhazi, Mohammed El Amine Ragala, et al.

    The timing of a breast cancer (BC) diagnosis has a significant psychological impact on patients. However, it reported that those eligible for treatment regimens based on neoadjuvant chemotherapy may experience high levels of depression, anxiety and distress. To cope with this situation, patients deploy psychological coping strategies. The aim of this study is to explore effective and ineffective psychological adjustment mobilized by Moroccan patients newly diagnosed with BC and before receiving neoadjuvant chemotherapy, as well as to identify their associations to socio-demographic and clinical determinants. A total of 209 patients were recruited in outpatient in oncology department in the public oncology hospital of Fez city, between 2021 and 2023. Ethics approval was obtained for this study and patients has signed an informed consent form. The questionnaire interview included socio-economic and clinical variables and the Arabic version of Mini-Mental Adjustment to Cancer (Mini-MAC) scale, which measures the strategies of mental adjustment to disease, as fighting spirit (FS), hopelessness/helplessness (HH), anxious preoccupations (AP), cognitive avoidance (CA), fatalism (FA), “maladaptive coping” and “adaptive coping”. Bivariate analysis of psychological adjustment strategies and sociodemographic and clinical variables was carried out using statistical tests according to the nature of the variables, to their normality and the homogeneity of their variances. Univariate and multivariate linear regression modelling was carried out using a forward “enter” regression procedure. A mean age of 47.43 ± 9.45 was found among participants. Assessment of mental adjustment to cancer using Mini-MAC scores revealed that psychological adjustment strategies with a higher mean score were FA, FS and “adaptive coping” strategies. Based mainly on multiple linear Regression, monthly family income was negatively associated with HH, and FS and positively linked to FA and “adaptive coping” strategies. Moreover, the left side as BC laterality was negatively associated with AP and “maladaptive coping” strategies. Furthermore, positive ER status was negatively associated with HH and “maladaptive coping” strategies and high Ki-67 levels were positively linked to AP. Programs to strengthen psychological adjustment in patients with BC candidates for NACT, taking into consideration the determinants found associated in this study, are of great importance since the first oncology consultation.


  • Immunotherapy in urothelial carcinoma of bladder : therapeutic advances in 2023

    by Lamiae Amaadour, Lamiae Nouiekh, Karima Oualla, Zineb Benbrahim, Samia Arifi, Nawfel Mellas

  • Open Access

    HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments

    by Ismail Essadi, Zineb Benbrahim, Mohamed Kaakoua, Thibaut Reverdy, Pauline Corbaux, Gilles Freyer

    For several years, the overexpression of the HER2 receptor in breast cancer has been correlated with a poor prognosis and an increased risk of developing brain metastases. Currently, the combination of anti-HER2 double blockade and taxane and trastuzumab emtansine (T-DM1) are considered the standard treatments for metastatic breast cancer overexpressing these receptors in the first and second line. Very recently, the development of a new antidrug conjugate, trastuzumab–deruxtecan, has improved the overall survival of patients, even in second-line treatment. However, trastuzumab–deruxtecan has become a new standard. Despite the benefits of these antidrug conjugates, this benefit in patients with brain metastases remains unclear. Tucatinib is a new tyrosine kinase inhibitor that has given hope for the treatment of these patients. The objective of this article was to review data on the established drugs and novel agents for HER2-positive MBC and to discuss how to incorporate anti-HER2 therapies in first and later-line settings.


  • Open Access

    Mediastinal NUT carcinoma: about a case report including immunotherapy in therapeutic management

    by Soukaina El Anssari, Youssef Elhaitmy, Lamiae Amaadour, Karima Oualla, Zineb Benbrahim, Samia Arifi, Mellas Nawfel

    NUT carcinoma (NC), also known as NUT midline carcinoma, is a rare, genetically defined and highly lethal undifferentiated carcinoma occurring in the midline location of the neck, head or mediastinum. We present the case of a 36-year-old Caucasian women who consulted for dyspnea, cough and night sweats. An injected scan showed a large mediastinal mass with lymph node invasion. Transbronchial biopsies confirmed the diagnosis of NUT carcinoma. The ribonucleic acid (RNA) panel molecular biological analysis concluded in the presence of a fusion transcript bromodomain-containing protein 4 (BRD4): NUTM1 (NUT Midline Carcinoma Family Member 1) consistent with the diagnosis of NUT carcinoma. A first line treatment was administered combining immunotherapy and chemotherapy. Through this case report, we will discuss the different therapeutic options and the benefit observed in terms of survival after the addition of immunotherapy.

  • Open Access

    Cancer Burden Among Arab World Males in 2020: The Need for a Better Approach to Improve Outcome

    by Layth Mula-Hussain, Hala Mahdi, Zhian Salah Ramzi, Marwan Tolba, Mohamad Saad Zaghloul, Zineb Benbrahim, Atlal Abusanad, Humaid Al-Shamsi, Adda Bounedjar, Abdul-Rahman Jazieh

    PURPOSE: Cancer is a leading cause of increased morbidity and mortality worldwide. This work aims to study the Arab world males' cancers (AMCs) and the similarities and disparities with the world males' cancers (WMCs) from different burden points of view. MATERIALS AND METHODS: A descriptive review of the 2020 Global Cancer Observatory revealed AMCs compared with the 2020 WMCs and the 2018 AMCs. Data on the top 27 AMCs were compared among the region's countries and the world groups. RESULTS: In 2020, a total estimate of 217,203 new AMCs, 2.2% of WMCs, with an average age-standardized rate of 133.5/100,000 population, compared with 222/100,000 population of WMCs, was observed. Death estimates were 148,395, 2.7% of WMCs, with an average age-standardized rate of 95/100,000 population, compared with 120.8/100,000 population of WMCs. The five-year prevalence was observed in 442,014, 1.8% of WMCs. The average AMC mortality to incidence ratio (MIR) was 0.68, compared with 0.55 in WMCs and 0.54 in Arab females. Lung cancer was the top in incidence and mortality, whereas penile cancer was the lowest. The range of MIRs among the 27 cancer types was 0.19-0.96. CONCLUSION: The descriptive review of the 2020 males' cancers in the Arab world revealed a relatively high MIR, compared with males' cancers worldwide and the females' cancers in the Arab world. This requires further evaluation to discern the underlying causes and address them systematically. More cancer control actions are warranted.


  • Open Access

    Prognostic Impact of Tumor Budding on Moroccan Colon Cancer Patients

    by Fatima El Agy, Sanae el Bardai, Laila Bouguenouch, Nada Lahmidani, Mohammed El Abkari, El Bachir Benjelloun, Abdelmalek Ousadden, Khalid Mazaz, Imane Toughrai, Sidi Adil Ibrahimi, et al.

    Background. Tumor budding is now emerging as one of the robust and promising histological factors that play an important role in colon cancer. In this study, we aimed to investigate the association between tumor budding and tumor clinicopathological factors, tumor molecular signature, and patient survival for the first time in a Moroccan population. Methods. We collected data of 100 patients operated from colon adenocarcinoma. Tumor budding was assessed on HES slides, according to the International Tumor Budding Consensus Conference 2016 recommendations. The expression of MMR proteins was performed by immunohistochemistry. KRAS and NRAS mutations testing was performed by Sanger sequencing and pyrosequencing. Results. High tumor budding grade (BUD 3) was found to be significantly associated with adverse clinicopathological features including older age ( ), presence of perineural invasion ( ), presence of vascular invasion ( ), distant metastases ( ), advanced TNM stage ( ), the occurrence of relapse ( ), and the high number of deceased cases ( ). Interestingly, we found that tumors with high-grade tumor budding were more likely to be microsatellite stable (MSS) ( ) and harbor more KRAS mutations ( ). Tumors with high-grade tumor budding were strongly associated with KRAS G12D mutation ( ). In all stages, high tumor budding was correlated with poorer overall survival ( ) and decreased relapse-free survival with a difference close to significance (( ). We concluded that high tumor budding was strongly associated with unfavorable clinicopathological features and special molecular biomarkers and effectively affects the overall survival of CC patients. Conclusions. Based on these findings and the ITBCC group recommendations, tumor budding should be taken into account along with other clinicopathologic factors in the risk assessment of colorectal cancer.


  • Open Access

    National approaches to managing cancer care: responses of countries in the MENA region to the COVID-19 pandemic

    by Zineb Benbrahim, Layth Mula-Hussain, Humaid O Al-Shamsi, Nagi El Saghir, Mushabbab Al Asiri, Bassim Al Bahrani, Muath Al Nassar, Adda Bounedjar, Zahera Fahed, Sami Khatib, et al.

    National approaches to managing cancer care: responses of countries in the MENA region to the COVID-19 pandemic Zineb Benbrahim1, Layth Mula-Hussai


  • Open Access

    Diffuse large cell type B breast lymphoma: case report

    by Lamyae Nouiakh, Karima Oualla, Imane Ouafki, Soumia Berrad, Hayat Erraichi, Younes Dkhissi, Lamiae Amaadour, Zineb Benbrahim, Samia Arifi, Meryem Boubou, et al.

  • Open Access

    Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives

    by Karima Oualla, Loay Kassem, Lamiae Nouiakh, Lamiae Amaadour, Zineb Benbrahim, Samia Arifi, Nawfel Mellas

    Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It accounts for 15%–20% of all breast cancers and is associated with an aggressive evolution and poor outcomes with the majority of recurrences and deaths occurring in the first 5 years. Chemotherapy remains the mainstay of treatment in the absence of effective targets, but the good understanding of immune tumor microenvironment, the identification of immune-related targets, and the role of tumor-infiltrating lymphocytes (TILs) in TNBC has allowed to develop promising immunotherapeutic strategies for this unique subset of breast cancer. Recently, immunotherapy is being extensively explored in TNBC and clinical trials have shown promising results. In this article, we tried to explain the rationale and mechanisms of targeting the immune system in TNBC, to report the results from recent clinical trials that put immunotherapy as a new standard of care in TNBC in addition to ongoing trials and future directions in the next decade.


  • Open Access

    Cancer in Moroccan elderly: the first multicenter transverse study exploring the sociodemographic characteristics, clinical profile and quality of life of elderly Moroccan cancer patients

    by Mounia Amzerin, Mohamed Layachi, Aziz Bazine, Rachid Aassab, Samia Arifi, Zineb Benbrahim, Mohamed Reda Khmamouche, Mouna Kairouani, Hanan Raiss, Noura Majid, et al.

    Background: Moroccan incidence of cancer is increasing with the lengthening of life expectancy. Data regarding elderly Moroccan cancer patients are lacking. In the context of our project aiming to develop an adapted version of the Comprehensive Geriatric Assessment CGA to the Moroccan population, we launched the first Moroccan multicenter transverse study to explore the characteristics of elderly Moroccan cancer patients. Methods: The study was conducted in nine Moroccan medical oncology departments. Patients were enrolled over 4 months. Inclusion criteria were patients aged 65 years or over with verified solid cancer. The questionnaire included four sections: socio-demographic and economic data, clinical data, vulnerability and EORTC-QLQ C30. We explored the entire included population. Then, we compared the results according to age (65–70 years old and ≥ 71 years old) and sex. We also explored the correlation between G8 scores and the ability to practice religion as an indicator of fitness level. Results: In total, 164 patients were enrolled. The mean age was 73.18 ± 6.01 years. The majority of patients were married, lived with their children and received their financial income from them. Fifteen percent of families asked to hide the diagnosis from the patient. Breast (23%), colorectal (15.9%) and lung (14%) cancers were the most frequent, and 83.5% had an abnormal G8. The majority of the patients were independent for basic daily activities. Female patients had poorer social and economic conditions. Abnormal G8 was correlated with religious practice and quality of life scores. Conclusion: This is the first multicenter prospective study designed to collect data on the lifestyle and clinical profiles of elderly Moroccan cancer patients as an Arab and Muslim population. Our study shows that it is a well-cared-for population with strong social ties. However, there is deep economic vulnerability, especially among women, requiring urgent care. Religious practice is an important daily activity for our elderly patients and should be included in the Moroccan CGA.